Jefferies initiates BioScrip (BIOS +3%) at Buy with a $17 price target citing expectations "for...

|By:, SA News Editor

Jefferies initiates BioScrip (BIOS +3%) at Buy with a $17 price target citing expectations "for sustained, robust top line and EBITDA growth over the next five years" and the likelihood of "incremental market share gains." On the latest CC, management told analyst Brian Tanquilut that the reduced interest expense from a debt refinancing would more than offset the increase in aggregate principal necessary to pay the associated redemption premium. (transcript)